German CLL Study Group
Quick facts
Phase 3 pipeline
- Fludarabine mono · Oncology
Fludarabine is a purine analog that inhibits DNA synthesis by blocking ribonucleotide reductase and incorporating into DNA, leading to cell death in rapidly dividing lymphocytes. - Fludarabine plus Cyclophosphamide · Oncology
Fludarabine and cyclophosphamide work together as a chemotherapy combination that damages cancer cell DNA and suppresses immune function to treat chronic lymphocytic leukemia. - Fludarabine plus Darbopoetin · Oncology
Fludarabine inhibits DNA synthesis in leukemic cells while darbopoetin stimulates red blood cell production to counteract chemotherapy-induced anemia.
Phase 2 pipeline
- CAL-101 · Oncology
CAL-101 is a selective, irreversible inhibitor of phosphatidylinositol 3-kinase (PI3K). - FCCam
- Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab
Phase 1 pipeline
- Alemtuzumab i.v. · Oncology
CD52 is a surface protein on mature lymphocytes; Alemtuzumab binds to CD52 and induces cell death. - Alemtuzumab s.c. · Oncology
CD52-targeting monoclonal antibody - Bendamustine, Rituximab, Lenalidomide
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: